Cite
MLA Citation
J. Cortes et al.. “1802 Overall survival (OS) from the phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) signaling inhibitor, in AR+ advanced triple-negative breast cancer (aTNBC).” European journal of cancer, vol. 51, n.d., pp. S265–. http://access.bl.uk/ark:/81055/vdc_100030628126.0x00000b